X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Novartis with SHASUN PHARMA - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NOVARTIS vs SHASUN PHARMA - Comparison Results

NOVARTIS    Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NOVARTIS SHASUN PHARMA NOVARTIS/
SHASUN PHARMA
 
P/E (TTM) x 364.8 123.9 294.4% View Chart
P/BV x 18.0 8.5 210.5% View Chart
Dividend Yield % 1.6 0.2 689.2%  

Financials

 NOVARTIS   SHASUN PHARMA
EQUITY SHARE DATA
    NOVARTIS
Mar-16
SHASUN PHARMA
Mar-14
NOVARTIS/
SHASUN PHARMA
5-Yr Chart
Click to enlarge
High Rs98294 1,042.5%   
Low Rs55646 1,219.7%   
Sales per share (Unadj.) Rs252.9214.2 118.1%  
Earnings per share (Unadj.) Rs62.15.3 1,164.6%  
Cash flow per share (Unadj.) Rs63.315.8 400.1%  
Dividends per share (Unadj.) Rs10.001.00 1,000.0%  
Dividend yield (eoy) %1.31.4 90.9%  
Book value per share (Unadj.) Rs363.653.3 681.7%  
Shares outstanding (eoy) m31.9656.62 56.4%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.00.3 931.8%   
Avg P/E ratio x12.413.1 94.5%  
P/CF ratio (eoy) x12.24.4 275.0%  
Price / Book Value ratio x2.11.3 161.4%  
Dividend payout %16.118.7 85.9%   
Avg Mkt Cap Rs m24,5803,958 621.1%   
No. of employees `0000.8NA-   
Total wages/salary Rs m1,8012,164 83.3%   
Avg. sales/employee Rs Th10,748.9NM-  
Avg. wages/employee Rs Th2,395.2NM-  
Avg. net profit/employee Rs Th2,641.1NM-  
INCOME DATA
Net Sales Rs m8,08312,127 66.7%  
Other income Rs m829229 361.6%   
Total revenues Rs m8,91312,356 72.1%   
Gross profit Rs m2341,009 23.2%  
Depreciation Rs m37594 6.2%   
Interest Rs m2415 0.4%   
Profit before tax Rs m1,025230 446.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m170 -5,566.7%   
Extraordinary Inc (Exp) Rs m1,6960-   
Tax Rs m752-73 -1,034.1%   
Profit after tax Rs m1,986302 657.4%  
Gross profit margin %2.98.3 34.8%  
Effective tax rate %73.4-31.7 -231.7%   
Net profit margin %24.62.5 986.3%  
BALANCE SHEET DATA
Current assets Rs m12,6786,884 184.2%   
Current liabilities Rs m2,4338,456 28.8%   
Net working cap to sales %126.7-13.0 -978.0%  
Current ratio x5.20.8 640.0%  
Inventory Days Days3362 53.1%  
Debtors Days Days22108 20.9%  
Net fixed assets Rs m694,970 1.4%   
Share capital Rs m160113 141.0%   
"Free" reserves Rs m11,4602,875 398.6%   
Net worth Rs m11,6213,020 384.8%   
Long term debt Rs m01,817 0.0%   
Total assets Rs m14,40013,347 107.9%  
Interest coverage x570.51.6 36,726.8%   
Debt to equity ratio x00.6 0.0%  
Sales to assets ratio x0.60.9 61.8%   
Return on assets %13.85.4 256.9%  
Return on equity %17.110.0 170.8%  
Return on capital %23.613.3 177.0%  
Exports to sales %0.746.4 1.6%   
Imports to sales %18.614.2 130.5%   
Exports (fob) Rs m605,622 1.1%   
Imports (cif) Rs m1,5031,728 87.0%   
Fx inflow Rs m1865,843 3.2%   
Fx outflow Rs m1,8212,173 83.8%   
Net fx Rs m-1,6353,669 -44.5%   
CASH FLOW
From Operations Rs m2,531398 636.5%  
From Investments Rs m-8,270-1,635 505.8%  
From Financial Activity Rs m-3861,309 -29.5%  
Net Cashflow Rs m-6,12571 -8,601.8%  

Share Holding

Indian Promoters % 0.0 39.2 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 2.0 3.6 55.6%  
FIIs % 1.6 17.6 9.1%  
ADR/GDR % 0.0 0.0 -  
Free float % 21.5 39.6 54.3%  
Shareholders   41,647 20,750 200.7%  
Pledged promoter(s) holding % 0.0 12.3 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NOVARTIS With:   ELDER PHARMA  FDC LTD.  SUN PHARMA  STRIDES SHASUN LTD  TTK HEALTHCARE  

Compare NOVARTIS With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Strong US Markets; SBI, Tata Steel & Other Top Cues to Sway the Markets Today(Pre-Open)

After opening the day in green, share markets in India witnessed negative trading activity throughout the day and ended the day on a weak note.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

Here's What You Should Do in this Market Crash(The 5 Minute Wrapup)

Feb 6, 2018

The market correction has provided a golden opportunity to buy five high-quality safe stocks.

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

When Small is Not Always Beautiful(Chart Of The Day)

Feb 6, 2018

Big companies enjoying tax deductions and exemptions have an edge over the small companies.

What Should Mutual Fund Investors Do After LTCG Tax Norms(Outside View)

Feb 6, 2018

PersonalFN explain what investors should after LTCG tax norms.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

NOVARTIS SHARE PRICE


Feb 16, 2018 (Close)

TRACK NOVARTIS

  • Track your investment in NOVARTIS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

COMPARE NOVARTIS WITH

MARKET STATS